This site will redirect to on April 7. Get details >

Human VEGF-A Platinum ELISA

Also known as: Vascular endothelial growth factor A, VPF

RUO: For Research Use Only. Not for use in diagnostic procedures.

These products are now available on Find out more >

SKU# BMS277/2*

Cat. No. Size
BMS277/2 96 tests
BMS277/2TEN 10 x 96 tests

Data for Human VEGF-A Platinum ELISA.

Click on image to view more information.

  • Data for Human VEGF-A Platinum ELISA.

Description: The human VEGF-A ELISA is an enzyme-linked immunosorbent assay for the quantitative detection of human VEGF-A. The human VEGF-A ELISA is for research use only. Not for diagnostic or therapeutic procedures.

One of the key molecules for angiogenesis and for the survival of the endothelium is vascular endothelial growth factor (VEGF-A). It is a specific endothelial cell mitogen and a strong vascular permeability factor (VPF).
VEGF-A is a heparin-binding glycoprotein, secreted as a homodimer of 45 kDa by many different cell types. VEGF-A also causes vasodilation through the nitiric oxide synthase pathway in endothelial cells and can activate migration in monocytes. Many different splice variants of VEGF-A have been described, but VEGF165 is the most predominant protein and anchors with its heparin binding domain to extracellular matrix and to heparin sulfate.

Examples where VEGF-A plays an important role are psoriasis andrheumatoid arthritis, as well as the ovarian hyperstimulation syndrome. Diabetic retinopathy is associated with high intraocular levels of VEGF-A, and inhibition of VEGF-A function may result in infertility by blockage of corpus luteum function. Direct demonstration of the importance of VEGF-A in tumor growth has been achieved using dominant negative VEGF receptors to block in vivo proliferation, as well as blocking antibodies to VEGF or to one of the VEGF receptors. VEGF-A transcription is highly activated by hypoxia and by oncogenes like H-ras and several transmembrane tyrosine kinases, such as epidermal growth factor receptor and ErbB2. Together these pathways account for a marked upregulation of VEGF-A in tumors compared to normal tissues and are often of prognostic importance and relevance. Targeting the VEGF signalling may be of major therapeutic importance for many diseases and serves as a basis for the design of future (anti)-angiogenic treatments.

Reactivity Human
Sample Volume 50 uL
Suitable Sample Types cell culture supernatant, serum, plasma (EDTA, citrate, heparin)
Sensitivity 7.9 pg/mL
Standard Curve Range 15.6 - 1,000 pg/mL
Components Aluminium pouch(es) with a Microwell Plate coated with polyclonal antibody to human VEGF-A
Biotin-Conjugate anti-human VEGF-A polyclonal antibody
Human VEGF-A Standard lyophilized, 2 ng/mL upon reconstitution
Sample Diluent
Assay Buffer Concentrate 20x (PBS with 1% Tween 20 and 10% BSA)
Wash Buffer Concentrate 20x (PBS with 1% Tween 20)
Substrate Solution (tetramethyl-benzidine)
Stop Solution (1M Phosphoric acid)
Adhesive Films
Reported Applications ELISA
TDS Link Download TDS
Related Products
Cat. No. Name Excite Emit Application Reg.
BMS277/2CE* Human VEGF-A Platinum ELISA ELISA CE

References: Plate,K.H.; Breier,G.; Weich,H.A.; Risau,W.. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992;359:845-848. (Link)

Neulen,J.; Yan,Z.; Raczek,S.; Weindel,K.; Keck,C.; Weich,H.A.; Marme,D.; Breckwoldt,M.. Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome. J.Clin.Endocrinol.Metab 1995;80:1967-1971. (Link)

Rodriguez-Garcia,M.I.; Fernandez,J.A.; Rodriguez,A.; Fernandez,M.P.; Gutierrez,C.; Torre-Alonso,J.C.. Annexin V autoantibodies in rheumatoid arthritis. Ann.Rheum.Dis. 1996;55:895-900. (Link)

Arbiser,J.L.; Moses,M.A.; Fernandez,C.A.; Ghiso,N.; Cao,Y.; Klauber,N.; Frank,D.; Brownlee,M.; Flynn,E.; Parangi,S.; Byers,H.R.; Folkman,J.. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc.Natl.Acad.Sci.U.S.A 1997;94:861-866. (Link)

Gasparini,G.; Toi,M.; Gion,M.; Verderio,P.; Dittadi,R.; Hanatani,M.; Matsubara,I.; Vinante,O.; Bonoldi,E.; Boracchi,P.; Gatti,C.; Suzuki,H.; Tominaga,T.. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J.Natl.Cancer Inst. 1997;89:139-147. (Link)

Carmeliet,P.; Collen,D.. Role of vascular endothelial growth factor and vascular endothelial growth factor receptors in vascular development. Curr.Top.Microbiol.Immunol. 1999;237:133-158. (Link)

Risau,W.. Mechanisms of angiogenesis. Nature 1997;386:671-674. (Link)

Klaus,G.G.; Choi,M.S.; Lam,E.W.; Johnson-Leger,C.; Cliff,J.. CD40: a pivotal receptor in the determination of life/death decisions in B lymphocytes. Int.Rev.Immunol. 1997;15:5-31. (Link)

Weindel,K.; Moringlane,J.R.; Marme,D.; Weich,H.A.. Detection and quantification of vascular endothelial growth factor/vascular permeability factor in brain tumor tissue and cyst fluid: the key to angiogenesis?. Neurosurgery 1994;35:439-448. (Link)

Senger,D.R.; Galli,S.J.; Dvorak,A.M.; Perruzzi,C.A.; Harvey,V.S.; Dvorak,H.F.. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983-985. (Link)